BACKGROUND AND RATIONALE
comorbidity, CVD, Diabetes, hypertension, diabetes
CARDIOVASCULAR DISEASE, CVD, HYPERTENSION, DIABETES, BLOOD, HYPERTENSION, TYPE 2 DIABETES, DIABETES
The number of adults with diabetes in the world has nearly quadrupled from 1980 to 2014, corresponding to a growing and aging population.Hypertension is a common comorbidity in patients with type 2 diabetes. Patients with a history of diabetes have a higher prevalence (66.3% vs 21.9%) and a lower control rate (4.7% vs 19.6%) of hypertension than those with normal glucose regulation in Chinese adults.Meta‐analyses of previous randomized clinical trials have demonstrated the benefit of lowering blood pressure (BP) to <140/<90 mm Hg in patients with diabetes.Therefore, the optimal systolic BP treatment goal for the prevention of cardiovascular disease (CVD) and all‐cause mortality among patients with diabetes remains unknown. The Blood Pressure Control Target in Diabetes (BPROAD) study was designed to test the hypothesis of whether intensive BP management to achieve a systolic BP target of <120 mm Hg has additional benefits over standard BP management to achieve a systolic BP target of <140 mm Hg over a period of up to 5 years in patients with type 2 diabetes. The findings from this study will help in the development of clinical guidelines for BP management among patients with diabetes.